{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '73']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', \"Genetic variation may impact a participant's response to therapy, susceptibility,\", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '74']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.7.', 'Appendix 7: Liver Safety: Required Actions and Follow-up', 'Assessments', 'Phase II liver chemistry stopping and increased monitoring criteria have been', 'designed to assure participant safety and evaluate liver event etiology', 'Phase II liver chemistry stopping criteria and required follow up assessments', 'Liver Chemistry Stopping Criteria', 'ALT-absolute', 'ALT 5xULN', 'ALT Increase', 'ALT 3xULN persists for >4 weeks', 'Bilirubin1, 2', 'ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin)', 'INR\u00b2', 'ALT > 3xULN and INR>1.5, if INR measured', 'Cannot', 'ALT: 3xULN and cannot be monitored weekly for 4 weeks', 'Monitor', 'Symptomatic\u00b3', 'ALT 3xULN associated with symptoms (new or worsening) believed', 'to be related to liver injury or hypersensitivity', 'Required Actions and Follow up Assessments', 'Actions', 'Follow Up Assessments', 'Immediately discontinue study treatment', 'Viral hepatitis serology4', 'Report the event to GSK within 24 hours', 'Obtain INR and recheck with each', 'liver chemistry assessment until the', 'Complete the liver event CRF and complete', 'transaminases values show', 'an SAE data collection tool if the event also', 'downward trend', 'meets the criteria for an SAE\u00b2', 'Obtain blood sample for', 'Perform liver chemistry event follow up', 'pharmacokinetic (PK) analysis, up', 'assessments', 'to 72 h after last dose5', 'Monitor the participant until liver', 'chemistries resolve, stabilize, or return to', 'Serum creatine phosphokinase', 'within baseline (see MONITORING', '(CPK) and lactate dehydrogenase', '(LDH).', 'below)', 'Fractionate bilirubin, if total', 'Do not restart/rechallenge participant', 'bilirubin 2xULN', 'with study treatment unless allowed per', 'protocol and GSK Medical Governance', 'Obtain complete blood count with', 'approval is granted (see below)', 'differential to assess eosinophilia', 'If restart/rechallenge not allowed per', 'Record the appearance or', 'protocol or not granted, permanently', 'worsening of clinical symptoms of', '75']\n\n###\n\n", "completion": "END"}